HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART
Patients with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) are at increased risk for developing Hodgkin's lymphoma (HL), a risk that has not decreased despite the success of combination antiretroviral therapy (cART) in the modern era. HIV-associated HL (HIV-HL) di...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2012/507257 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560807411449856 |
|---|---|
| author | Caron A. Jacobson Jeremy S. Abramson |
| author_facet | Caron A. Jacobson Jeremy S. Abramson |
| author_sort | Caron A. Jacobson |
| collection | DOAJ |
| description | Patients with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) are at increased risk for developing Hodgkin's lymphoma (HL), a risk that has not decreased despite the success of combination antiretroviral therapy (cART) in the modern era. HIV-associated HL (HIV-HL) differs from HL in non-HIV-infected patients in that it is nearly always associated with Epstein-Barr virus (EBV) and more often presents with high-risk features of advanced disease, systemic “B” symptoms, and extranodal involvement. Before the introduction of cART, patients with HIV-HL had lower response rates and worse outcomes than non-HIV-infected HL patients treated with conventional chemotherapy. The introduction of cART, however, has allowed for the delivery of full-dose and dose-intensive chemotherapy regimens with improved outcomes that approach those seen in non-HIV infected patients. Despite these significant advances, HIV-HL patients remain at increased risk for treatment-related toxicities and drug-drug interactions which require careful attention and supportive care to insure the safe administration of therapy. This paper will address the modern diagnosis, risk stratification, and therapy of HIV-associated HL. |
| format | Article |
| id | doaj-art-52b5ef8979bc4b1291b744ae6879d708 |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-52b5ef8979bc4b1291b744ae6879d7082025-02-03T01:26:43ZengWileyAdvances in Hematology1687-91041687-91122012-01-01201210.1155/2012/507257507257HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cARTCaron A. Jacobson0Jeremy S. Abramson1Dana-Farber Cancer Institute, Boston, MA 02215, USACenter for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USAPatients with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) are at increased risk for developing Hodgkin's lymphoma (HL), a risk that has not decreased despite the success of combination antiretroviral therapy (cART) in the modern era. HIV-associated HL (HIV-HL) differs from HL in non-HIV-infected patients in that it is nearly always associated with Epstein-Barr virus (EBV) and more often presents with high-risk features of advanced disease, systemic “B” symptoms, and extranodal involvement. Before the introduction of cART, patients with HIV-HL had lower response rates and worse outcomes than non-HIV-infected HL patients treated with conventional chemotherapy. The introduction of cART, however, has allowed for the delivery of full-dose and dose-intensive chemotherapy regimens with improved outcomes that approach those seen in non-HIV infected patients. Despite these significant advances, HIV-HL patients remain at increased risk for treatment-related toxicities and drug-drug interactions which require careful attention and supportive care to insure the safe administration of therapy. This paper will address the modern diagnosis, risk stratification, and therapy of HIV-associated HL.http://dx.doi.org/10.1155/2012/507257 |
| spellingShingle | Caron A. Jacobson Jeremy S. Abramson HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART Advances in Hematology |
| title | HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART |
| title_full | HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART |
| title_fullStr | HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART |
| title_full_unstemmed | HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART |
| title_short | HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART |
| title_sort | hiv associated hodgkin s lymphoma prognosis and therapy in the era of cart |
| url | http://dx.doi.org/10.1155/2012/507257 |
| work_keys_str_mv | AT caronajacobson hivassociatedhodgkinslymphomaprognosisandtherapyintheeraofcart AT jeremysabramson hivassociatedhodgkinslymphomaprognosisandtherapyintheeraofcart |